A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections
- Registration Number
- NCT02678598
- Lead Sponsor
- Astellas Pharma China, Inc.
- Brief Summary
The objective of this study is to evaluate the efficacy of intravenous micafungin for the empirical antifungal therapy, pre-emptive antifungal therapy, diagnostic driven antifungal therapy or targeted antifungal therapy patients with invasive fungal infections caused by Candida sp. or Aspergillus sp. (fungemia, respiratory mycosis, gastrointestinal mycosis) in adult patients in China.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2555
Inclusion Criteria
- Patients who received Micafungin as empirical antifungal therapy, pre-emptive antifungal therapy, diagnostic driven antifungal therapy or targeted antifungal therapy
- Patients received Micafungin treatment at least 1 dose
Exclusion Criteria
- Patients received Micafungin treatment combined with other antifungal drugs at the same time
- Neither efficacy or safety can be evaluated because of missing data, confused record
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Micafungin group Micafungin -
- Primary Outcome Measures
Name Time Method Overall success rate Up to 12 months Overall success rate=number of overall success patients/number of patients for efficacy evaluation × 100%
- Secondary Outcome Measures
Name Time Method Overall incidence and severity of adverse events Up to 12 months Overall incidence and severity of adverse drug reactions Up to 12 months